Gene Therapy In Oncology Market Research Report- Ken Research


Gene therapy combines reduced treatment duration with a higher chance of cure unlike conventional oncology treatments such as chemotherapy. However this novel therapeutic approach requires the delivery of genetic material to the patient, an uncharted territory in oncology which will necessitate the implementation of new regulatory guidelines and the restructuring of existing treatment algorithms in various oncology indications.

The current clinical development of gene therapies in oncology is dominated by small size biotech and pharmaceutical companies. Astrazeneca is the only large pharmaceutical company with an in-house gene therapy in late stage clinical development. Other major players such as johnson & johnson have the exclusive worldwide rights to develop and commercialize geron’s imetelstat, while merck & co. And bms are evaluating their respective checkpoint inhibitor therapies with many of the phase iii and phase ii candidates in the cancer gene therapy pipeline.

Develop business strategies by understanding the trends shaping and driving the gene therapy in the oncology space in the 8mm. Formulate effective sales and marketing strategies by understanding the current competitive landscape and by analyzing the portfolios of various competitors. Identify areas of unmet need within the cancer gene therapy market to help drive research and development towards future market opportunities. Gain insights to help plan and design your clinical trials. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Identify key pricing and reimbursement strategies.

To Know More, Click On The Link Below:-

Related Reports:-

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Comments are closed.